

Historical Information

Provided by: ASLAN PHARMACEUTICALS LIMITED

SEQ_NO 2 Date of announcement 2019/03/22 Time of announcement 16:27:39

Subject Announcement on the Board resolution of convening the Annual General Meeting of 2019

Date of events 2019/03/22 To which item it meets paragraph 17

Statement

- 1.Date of the board of directors resolution:2019/03/22
- 2.Date for convening the shareholders' meeting:2019/06/21
- 3.Location for convening the shareholders' meeting:
Taipei International Convention (TICC), Elegance Lounge
(4F, 1, Hsin-Yi Road, Section 5, Xinyi Dist. Taipei)
- 4.Cause or subjects for convening the meeting (1)Report Items:
 - i. Business performance of 2018.
 - ii. Business report and financial statements of 2018 that are reviewed by the Audit Committee.
- 5.Cause or subjects for convening the meeting (2)Matters for Ratification:
 - i. Business report and financial statements of 2018.
 - ii. Deficit compensation for 2018.
- 6.Cause or subjects for convening the meeting (3)Matters for Discussion:
 - i. Amendments to the Company's sixth Amended and Restated Memorandum and Articles of Association.
 - ii. Amendments to the Rules and Procedures of Shareholders' Meetings.
 - iii. Amendments to the Procedures for Making Loan to Others.
 - iv. Amendments to the Procedures for Acquisition or Disposal of Assets.
 - v. To determine the total number of directors be elected for this term be 7 directors (including 3 independent directors).
- 7.Cause or subjects for convening the meeting (4)Elections:
 - i. To re-elect 7 directors (including 3 independent directors) of the board.
- 8.Cause or subjects for convening the meeting (5)Other Proposals:
 - i. To release the newly elected directors (including independent directors) from non-competition restrictions.
- 9.Cause or subjects for convening the meeting (6)Extemporary Motions:
None.
- 10.Book closure starting date:2019/04/23
- 11.Book closure ending date:2019/06/21
- 12.Any other matters that need to be specified:
 - i. The voting rights at this AGM may be exercised by means of electronic transmission, the exercise period starts from 22 May 2019 through 18 June 2019. Shareholders should access the designated platform of electronic voting for instructions
(link to: [https:// www.stockvote.com.tw](https://www.stockvote.com.tw)).
 - ii. The period for shareholders to submit the nomination of director (including independent director) candidates is from 15 April 2019 through 24 April 2019 in accordance with Article 192-1 of the Company Act and Article 92 of the Company's M&AA. Please send the nomination to ASLAN Pharmaceuticals at 35F, No.68, Sec.5, Zhongxiao East Road Taipei 110, Taiwan.
 - iii. The period for shareholders to submit proposals is from 15 April 2019 through 24 April 2019 in accordance with Article 172-1 of the Company Act. Please send proposals to ASLAN Pharmaceuticals at 35F, No.68, Sec.5, Zhongxiao East Road Taipei 110, Taiwan.
 - iv. The amendments to the Procedures for Acquisition or Disposal of Assets are made in accordance with the latest updates on regulations by FSC and are hereby announced as per commitment to TPEx as stated in the approval letter No.10601001421 dated 2017/01/26.